TP53 mutations portend a dismal prognosis in MCL, and analysis of the TP53 cohort from the Nordic MCL2 and MCL3 trials suggests that these patients do not benefit from cytarabine-containing induction chemotherapy or ASCT49. Here, TP53 is linked to mantle cell lymphoma.